pulseadmin
150 Views
Reported consolidated revenue growth of 7% on a like-for-like basis, after adjusting for Branded Formulations India (BFI) revenues & income from BFI part divestment in Q3FY24 and gain from Biocon’s stake dilution in Bicara Therapeutics, which are not a part of Q3FY25 revenue.
Reported Net…
Enter your account data and we will send you a link to reset your password.
To use social login you have to agree with the storage and handling of your data by this website. %privacy_policy%
AcceptHere you'll find all collections you've created before.
GIPHY App Key not set. Please check settings